Simulations Plus, Inc. (SLP)
| Market Cap | 368.43M |
| Revenue (ttm) | 78.56M |
| Net Income (ttm) | 7.26M |
| Shares Out | 20.11M |
| EPS (ttm) | 0.36 |
| PE Ratio | 50.87 |
| Forward PE | 40.19 |
| Dividend | $0.06 (0.33%) |
| Ex-Dividend Date | Jul 29, 2024 |
| Volume | 491,548 |
| Open | 17.28 |
| Previous Close | 17.45 |
| Day's Range | 17.25 - 18.95 |
| 52-Week Range | 16.72 - 49.05 |
| Beta | 0.97 |
| Analysts | Buy |
| Price Target | 40.40 (+120.52%) |
| Earnings Date | Jul 14, 2025 |
About SLP
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models,... [Read more]
Financial Performance
In 2024, Simulations Plus's revenue was $70.01 million, an increase of 17.52% compared to the previous year's $59.58 million. Earnings were $9.95 million, a decrease of -0.07%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for SLP stock is "Buy." The 12-month stock price target is $40.4, which is an increase of 120.52% from the latest price.
News
Simulations Plus Announces Rescheduling of Third Quarter Fiscal 2025 Earnings Release and Conference Call
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled perf...
Simulations Plus: Further Downside Is Likely (Rating Downgrade)
Simulations Plus' Q3 FY25 results missed expectations, with revenue guidance cut sharply due to biopharma market weakness and services segment volatility. Organic growth continues to decelerate and th...
Simulations Plus Slashes Guidance Amid Biotech Spending Cuts, Analyst Expresses Doubt
Simulations Plus Inc SLP stock tanked after the company lowered its fiscal 2025 sales outlook.
Simulations Plus to Participate in the Citizens Medical Devices and Healthcare Services Forum
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance an...
Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled perf...
Simulations Plus Releases ADMET Predictor® 13
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intel...
Simulations Plus Releases DILIsym® 11
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intel...
Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intel...
Simulations Plus: Benefiting From FDA Modernization And AI
Simulations Plus, Inc. offers AI-based software tools for drug discovery and optimization, significantly reducing R&D time and costs for pharmaceutical research. SLP's diverse software portfolio, incl...
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.
Simulations Plus: I See Promising Growth, But I'm Staying Neutral
Simulations Plus, Inc. excels with its AI-driven biosimulation platforms, aiding drug development, but faces challenges with margin erosion and cash flow pressures. Despite strong revenue growth and p...
Simulations Plus, Inc. (SLP) Q2 2025 Earnings Call Transcript
Simulations Plus, Inc. (NASDAQ:SLP) Q2 2025 Earnings Conference Call April 3, 2025 5:00 PM ET Company Participants Lisa Fortuna - IR, Financial Profiles Shawn O'Connor - CEO Will Frederick - CFO & CO...
Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intel...
Top 3 Health Care Stocks That Are Set To Fly This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Simulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call Date
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance an...
Simulations Plus to Present at the KeyBanc Capital Markets Virtual Healthcare Investor Forum
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance an...
Simulations Plus to Participate in Upcoming Healthcare Investor Conferences
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance an...
Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements
RESEARCH TRIANGLE, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and...
Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--SLP highlighted its impact on the pharma industry through support of the development of a majority of the drugs approved by the U.S. FDA in 2024.
Simulations Plus Supported Development of Every FDA-Approved Drug in 2024
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--SLP highlighted its impact on the pharmaceutical industry through supporting the development of 100% of the drugs approved by the U.S. FDA in 2024.
Simulations Plus, Inc. (SLP) Q1 2025 Earnings Call Transcript
Simulations Plus, Inc. (NASDAQ:SLP) Q1 2025 Earnings Conference Call January 7, 2025 5:00 PM ET Company Participants Lisa Fortuna - IR, Financial Profiles Shawn O'Connor - CEO Will Frederick - CFO & ...
Simulations Plus Reports First Quarter Fiscal 2025 Financial Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intel...
Simulations Plus Announces First Quarter Fiscal Year 2025 Earnings and Conference Call Date
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions...
Simulations Plus to Participate in the BTIG Digital Health Forum
LANCASTER, Calif.--(BUSINESS WIRE)--CEO of Simulations Plus, Shawn O'Connor, will participate in a panel discussion at the virtual BTIG Digital Health Forum on Monday, November 25, 2024.
Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, in partnership with the University of Connecticut, was awarded a new FDA grant to investigate additional LAI product technologies.